BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Atai Life Sciences Stock Surges 15% on Promising Antidepressant Trial Results
Atai Life Sciences Stock Surges 15% on Promising Antidepressant Trial Results
14
1
BTCCSquare news:
Atai Life Sciences (ATAI) shares soared nearly 15% Tuesday, defying a 0.6% market downturn, after revealing positive phase 2a results for its experimental antidepressant BPL-003. The open-label study demonstrated rapid, clinically meaningful effects lasting up to three months in treatment-resistant depression patients.
The biotech firm, collaborating with UK-based Beckley Psytech, reported continued efficacy at higher doses as measured by the MADRS scale. This marks the second consecutive successful trial for the compound, positioning it for potential phase 3 advancement pending regulatory discussions.
By:
